Julia G.  Butchko net worth and biography

Julia Butchko Biography and Net Worth

Insider of Immunovant

Prior to joining Immunovant, Julia oversaw strategy and operations as Chief of Staff for the $4 billion Immunology and Neuroscience businesses at Lilly. She previously served as Vice President of Lilly’s Oncology Portfolio Management and Clinical Development teams where she was responsible for over 100 global clinical trials, including immune-oncology collaborations with Merck, Bristol-Myers Squibb, and AstraZeneca. Earlier in her career, Julia held significant roles in product development, marketing, manufacturing, and quality.

She holds a B.S. in Chemistry from the State University of New York at Fredonia, a Ph.D. in Chemistry from Pennsylvania State University, and a Business Certificate from Indiana University’s Kelley School of Business.

What is Julia G. Butchko's net worth?

The estimated net worth of Julia G. Butchko is at least $9.08 million as of July 9th, 2024. Dr. Butchko owns 446,853 shares of Immunovant stock worth more than $9,084,521 as of February 15th. This net worth approximation does not reflect any other investments that Dr. Butchko may own. Additionally, Dr. Butchko receives an annual salary of $531,000.00 as Insider at Immunovant. Learn More about Julia G. Butchko's net worth.

How old is Julia G. Butchko?

Dr. Butchko is currently 53 years old. There are 6 older executives and no younger executives at Immunovant. The oldest executive at Immunovant is Dr. William L. Macias M.D., Ph.D., Chief Medical Officer, who is 65 years old. Learn More on Julia G. Butchko's age.

What is Julia G. Butchko's salary?

As the Insider of Immunovant, Inc., Dr. Butchko earns $531,000.00 per year. There are 3 executives that earn more than Dr. Butchko. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Julia G. Butchko's salary.

How do I contact Julia G. Butchko?

The corporate mailing address for Dr. Butchko and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at info@immunovant.com. Learn More on Julia G. Butchko's contact information.

Has Julia G. Butchko been buying or selling shares of Immunovant?

Julia G. Butchko has not been actively trading shares of Immunovant within the last three months. Most recently, Julia G. Butchko sold 1,527 shares of the business's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $28.06, for a transaction totalling $42,847.62. Following the completion of the sale, the insider now directly owns 446,853 shares of the company's stock, valued at $12,538,695.18. Learn More on Julia G. Butchko's trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. During the last twelve months, insiders at the sold shares 40 times. They sold a total of 241,656 shares worth more than $6,778,366.96. The most recent insider tranaction occured on January, 22nd when CTO Jay S Stout sold 2,195 shares worth more than $51,780.05. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 1/22/2025.

Julia G. Butchko Insider Trading History at Immunovant

See Full Table

Julia G. Butchko Buying and Selling Activity at Immunovant

This chart shows Julia G Butchko's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $20.33
Low: $19.89
High: $20.49

50 Day Range

MA: $23.87
Low: $19.22
High: $28.94

2 Week Range

Now: $20.33
Low: $19.07
High: $39.55

Volume

1,241,001 shs

Average Volume

1,356,782 shs

Market Capitalization

$3.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65